Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis

Trial Profile

Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Amisulpride (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors Acacia Pharma
  • Most Recent Events

    • 12 Aug 2016 Detailed data from this trial will be presented in scientific meetings and submitted for publication in a peer-reviewed journal, as reported in an Acacia Pharma media release.
    • 12 Aug 2016 Primary endpoint has been met. (Success in primary PONV treatment, defined as no emetic episodes from 30 minutes to 24 hours after administration of study medication and no administration of further anti-emetic medication at any time in the 24-hour period after administration of study medication.), as reported in an Acacia Pharma media release.
    • 12 Aug 2016 Results published in an Acacia Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top